LHLing Hu

Ling Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ling Hu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaomei Wang

    Department of Neurosurgery, Wuhan Asia General Hospital Affiliated to Wuhan University of Science and Technology, Department of Pharmacy, Institute of Pharmaceutical Process, Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei Province, China

    3 shared publications
  • Hanning Xu

    Clinical Research Center of Gastroenterology Department, Tianyou Hospital, Affiliated to College of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei

    1 shared publication
  • Huan Li

    Clinical Research Center of Gastroenterology Department, Tianyou Hospital, Affiliated to College of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei

    1 shared publication
  • Jinling Zhang

    Wuhan Fourth Hospital, Wuhan Orthopedic Hospital, Wuhan 430033, China

    1 shared publication
  • Lingzi Zheng

    Tianyou Hospital, Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430064, China

    1 shared publication
  • Sheng Yan

    Tianyou Hospital, Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430064, China

    1 shared publication

Latest Publications

  • Open Access

    Uncovering core stemness biomarkers in HBV-HCC through integrated multi-omics

    by Hanning Xu, Huan Li, Ling Hu, Xiaomei Wang

    Chronic hepatitis B virus (HBV) infection is a major etiology of hepatocellular carcinoma (HCC), with cancer stem cells (CSCs) playing a critical role in tumor progression and therapeutic resistance. However, the specific mechanisms linking HBV infection to stemness features in HBV-associated HCC (HBV-HCC) remain incompletely defined. To identify potential regulators, we conducted an integrated in silico multi-omics analysis using single-cell and bulk transcriptomic datasets. Comparative stemness scoring across major cell populations prioritized the endothelial compartment for further analysis. Subsequent pseudotime trajectory and CytoTRACE2 analysis of single-cell RNA sequencing (scRNA-seq) data identified Cluster 4 (C4) as a putative stemness-associated endothelial subpopulation, from which 21 differentially positive-HBV-expressed genes (DPEGs) were derived. In bulk RNA sequencing (bulk RNA-seq), weighted gene co-expression network analysis (WGCNA) identified genes strongly correlated with stemness in the blue module. Cross-referencing scRNA-seq and bulk RNA-seq yielded 52 shared genes. Random Forest feature selection prioritized two high-confidence biomarkers: SSR2 and UBE2D3 . A combined diagnostic model based on these two genes showed favorable performance across independent cohorts with bootstrap-supported validation, and survival analyses indicated that high SSR2 expression and low UBE2D3 expression were associated with poor clinical outcomes. Mechanistically, pathway activity correlation analyses revealed that SSR2 and UBE2D3 are significantly associated with endoplasmic reticulum stress (ERS), and mTOR signaling, suggesting a potential coordinated role in regulating viral persistence and stemness maintenance. Overall, our findings propose SSR2 and UBE2D3 as candidate diagnostic and prognostic biomarkers, providing a hypothesis-generating framework for developing targeted therapeutic strategies against HBV-HCC.

  • Open Access

    Diverse functional roles of miR-128-3p in human diseases: Focus on its roles in human cancer

    by Lingzi Zheng, Sheng Yan, Jinling Zhang, Weisen Ning, Xiaoliu Liu, Xiaomei Wang, Ling Hu

    The microRNA known as miR-128-3p demonstrates widespread tissue-specific expression with its genetic locus situated on human chromosome 2 (2q21.3), and is a multifunctional regulator with tissue-specific expression patterns that critically influences cellular homeostasis and disease pathogenesis. By engaging with the 3′ untranslated region (3′ UTR) of target mRNA molecules, miR-128-3p exquisitely modulates gene expression levels, thereby orchestrating cellular proliferation, immune responses, metabolic equilibrium, and tumorigenesis. Studies on miR-128-3p in different cancers have revealed diverse expression patterns and functional roles. Intriguingly, due to its ability to target multiple genes and signaling pathways, as well as being regulated by various genes themselves, miR-128-3p exhibits both tumor-suppressive and oncogenic effects under neoplastic conditions. This review summarizes the expression patterns and complex regulatory mechanisms of miR-128-3p across various cancers. A profound understanding of the significance and regulation of miR-128-3p in cancer will drive the development of innovative therapeutic strategies using this molecule for combating human cancer and immune-related disorders.


  • Open Access

    Advancements related to probiotics for preventing and treating recurrent respiratory tract infections in children

    by Yali Zhang, Yingying Xu, Ling Hu, Xiaomei Wang

    Recurrent respiratory tract infections (RRTIs) are a common condition in pediatrics and significantly impact children's quality of life; however, their pathogenesis and contributing factors are not yet fully elucidated. Probiotics have recently emerged as promising agents for modulating intestinal microecology and have gained considerable attention in clinical research on preventing and treating RRTIs in children. This article provides an initial overview of the concept, classification, and mechanisms underlying probiotics. It emphasizes their beneficial effects on respiratory health by modulating intestinal microbial equilibrium, augmenting immune system functionality, and attenuating inflammatory responses. Subsequently, we examine existing research regarding the use of probiotics in pediatric RRTIs. Numerous clinical trials have unequivocally demonstrated that supplementing with probiotics can significantly reduce both the frequency and severity of RRTIs in children while also simultaneously decreasing antibiotic usage. However, there are ongoing controversies and challenges in current research concerning the influence of probiotic type, dosage, duration of use, and other factors on efficacy. Furthermore, variations have been observed across different studies. Additionally, it is crucial to further evaluate the safety and potential long-term side effects associated with probiotic use in children with RRTIs. In conclusion, we propose future research directions including conducting more high-quality randomized controlled trials to optimize application strategies for probiotics alongside other treatments while considering variations based on age and health conditions among pediatric populations. Finally, in summary although probiotics exhibit promising benefits in preventing and treating RRTIs in children; additional studies are necessary to refine their application strategies ensuring both safety and effectiveness.